You are here: Home: Audio Program Guide: BCU Think Tank 1 | 2008 Audio: BCU Think Tank 1 | 2008
 

 
  Go to Management of Metastatic Disease
Go to Adjuvant Therapy


 

To listen to individual tracks, click the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


Section 1:

Management of Metastatic Disease
   Click here to download the entire section  
Track 1 First-line therapy for hormone receptor-positive, HER2-positive metastatic breast cancer (mBC)
Track 2 Treatment of HER2-positive disease recurring after adjuvant trastuzumab
Track 3 Case discussion: A premenopausal woman with triple-negative breast cancer who rapidly developed mBC after adjuvant dose-dense ACarrow paclitaxel
Track 4 Impact of patient relapse on the oncologist and healthcare team
Track 5 Balancing hope and realism in communications with patients
Track 6 Value of prolonged progression-free survival in mBC

Track 7 Case follow-up: A dramatic response to paclitaxel/bevacizumab
Track 8 Proposed NSABP trial B-45: Sunitinib versus placebo for patients with residual disease after neoadjuvant chemotherapy
Track 9 NSABP-B-40: Neoadjuvant therapy adding capecitabine or gemcitabine to docetaxel when administered before AC with or without bevacizumab
Track 10 Cardiac safety of adjuvant bevacizumab with dose-dense ACarrow nanoparticle albumin-bound (nab) paclitaxel
Track 11 Proposed randomized Phase II study of nab paclitaxel with or without sunitinib followed or preceded by doxorubicin and daily oral cyclophosphamide with G-CSF for locally advanced or inflammatory breast cancer
Track 12 Efficacy and tolerability of nab paclitaxel versus standard formulation paclitaxel
Track 13 Phase III study of bevacizumab with weekly paclitaxel, nab paclitaxel or ixabepilone in mBC
Track 14 Emerging data with the novel epothilone B analog ixabepilone
Track 15 Perspective on the development of nab paclitaxel and the epothilones
Track 16 Children coping with a parent’s cancer and death
Track 17 Use of capecitabine with or without bevacizumab for minimally symptomatic or asymptomatic mBC
Track 18 Clinical trials evaluating fulvestrant in combination with aromatase inhibitors in mBC

Track 19 Overall survival as an endpoint in clinical trials in mBC

Section 2:

Adjuvant Therapy
   Click here to download the entire section  
Track 1 Long-term natural history of hormone receptor-positive breast cancer and the impact of aromatase inhibitors
Track 2 Optimal endocrine therapy for premenopausal patients with hormone receptor-positive breast cancer and chemotherapy-induced amenorrhea
Track 3 Extended adjuvant endocrine therapy for postmenopausal patients
Track 4 Adjuvant therapy considerations for premenopausal women
Track 5 One hundred-month follow-up of patients in the ATAC trial
Track 6 RT-PCR and quantitative assessment of ER to predict response to hormonal therapy

Track 7 Role of progesterone receptor (PR) as a prognostic and predictive factor
Track 8 Case discussion: A woman in her early seventies with a second, contralateral breast tumor that was HER2-positive
Track 9 Selection of adjuvant therapy for an older woman with a 2-cm, node-negative, ER-negative, PR-negative, HER2-positive breast tumor
Track 10 Perspectives on the tolerability of the TCH regimen
Track 11 Anthracycline-related toxicities in the elderly
Track 12 Case follow-up: Docetaxel/cyclophosphamide (TC) with trastuzumab followed by trastuzumab
Track 13 Role of carboplatin in trastuzumab-containing regimens
Track 14 Updated toxicity data from the NCCTG-N9831 adjuvant trial of trastuzumab
Track 15 HER2 status and response to adjuvant trastuzumab
Track 16 Proposed trial of TC with or without trastuzumab for patients with HER2 IHC 1+/2+, FISH-negative early breast cancer
Track 17 Findings from trials of adjuvant trastuzumab in patients with “HER2-negative” breast cancer
Track 18 Misnomer in identifying HER2 low-expressing/normal tumors as HER2-negative
Track 19 Antibody-dependent cellular cytotoxicity as a potential mechanism of action for adjuvant trastuzumab
Track 20 Rationale for a prospective clinical trial of adjuvant trastuzumab for IHC 1+/2+, FISH-negative tumors
Track 21 Reevaluation of the HER2 cutoff with nonlinear assays

Track 22 Adjuvant therapy for patients with small, node-negative, HER2-positive breast tumors
Track 23 Rationale for the next generation of adjuvant clinical trials in HER2-positive early breast cancer
Track 24 Proposed NSABP/CIRG BETH adjuvant trial of chemotherapy and trastuzumab with or without bevacizumab
Track 25 Potential role of angiogenesis in HER2-positive tumors
Track 26 Case discussion: A woman with a 1.1-cm, Grade II, hormone receptor-positive, HER2-negative, node-positive breast tumor
Track 27 Clinical use of the Oncotype DX™ assay for patients with node-positive disease
Track 28 Caveats in the use of the Oncotype DX assay in clinical decision-making for patients with positive nodes
Track 29 Use of the Oncotype DX assay with the Adjuvant! Online model to assist in clinical decision-making
Track 30 Identification of patients who may benefit from an Oncotype DX assay